Celcuity (NASDAQ:CELC) Stock Price Up 7.9% - What's Next?

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) shot up 7.9% during mid-day trading on Wednesday . The stock traded as high as $13.45 and last traded at $13.48. 53,312 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 242,636 shares. The stock had previously closed at $12.49.

Analysts Set New Price Targets

CELC has been the topic of several analyst reports. HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of Celcuity in a research report on Monday, May 19th. Needham & Company LLC restated a "buy" rating and issued a $29.00 price objective on shares of Celcuity in a report on Monday. Finally, Stifel Nicolaus initiated coverage on Celcuity in a research report on Tuesday. They issued a "buy" rating and a $30.00 target price on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $28.40.

Celcuity Price Performance

The stock has a market capitalization of $522.23 million, a P/E ratio of -4.55 and a beta of 0.45. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61. The company's 50-day simple moving average is $11.46 and its 200-day simple moving average is $11.25.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09. As a group, sell-side analysts expect that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Celcuity

Large investors have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP increased its holdings in shares of Celcuity by 59.0% in the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company's stock valued at $43,046,000 after purchasing an additional 1,579,182 shares during the last quarter. Soleus Capital Management L.P. grew its stake in Celcuity by 106.0% in the 4th quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company's stock valued at $33,577,000 after buying an additional 1,319,700 shares during the last quarter. Vanguard Group Inc. grew its stake in Celcuity by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock valued at $21,624,000 after buying an additional 24,429 shares during the last quarter. Geode Capital Management LLC raised its holdings in Celcuity by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 692,372 shares of the company's stock valued at $9,065,000 after acquiring an additional 62,003 shares during the period. Finally, Janus Henderson Group PLC acquired a new stake in Celcuity during the fourth quarter worth approximately $8,468,000. Institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.